News | May 18, 2021
Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Subscribe To Our Newsletter & Stay Updated
